Originally published as JCO Early Release 10.1200/JCO.2005.01.032 on October 4 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jayson, G.C. Articles by Jackson, A. Search for Related Content PubMed PubMed Citation Articles by Jayson, G.C. Articles by Jackson, A. Social Bookmarking                            What's this?

Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume

G.C. Jayson, G.J.M. Parker, S. Mullamitha, J.W. Valle, M. Saunders, L. Broughton, J. Lawrance, B. Carrington, C. Roberts, B. Issa, D.L. Buckley, S. Cheung, K. Davies, Y. Watson, K. Zinkewich-Péotti, L. Rolfe, A. Jackson

From the Cancer Research UK Departments of Medical Oncology and Radiology, Christie Hospital; Imaging Science and Biomedical Engineering, University of Manchester, Manchester; Oncology Group, Celltech R & D Ltd, Slough, UK

Address reprint requests to Gordon Jayson, FRCP, PhD, Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, United Kingdom; e-mail: Gordon.Jayson{at}christie-tr.nwest.nhs.uk.

PURPOSE: CDP860 is an engineered Fab' fragment-polyethylene glycol conjugate, which binds to and blocks the activity of the beta-subunit of the platelet-derived growth factor receptor (PDGFR-ß). Studies in animals have suggested that PDGFR-ß inhibition reduces tumor interstitial fluid pressure, and thus increases the uptake of concomitantly administered drugs. The purpose of this study was to determine whether changes in tumor vascular parameters could be detected in humans, and to assess whether CDP860 would be likely to increase the uptake of a concurrently administered small molecule in future studies.

PATIENTS AND METHODS: Patients with advanced ovarian or colorectal cancer and good performance status received intravenous infusions of CDP860 on days 0 and 28. Patients had serial dynamic contrast-enhanced magnetic resonance imaging studies to measure changes in tumor vascular parameters.

RESULTS: Three of eight patients developed significant ascites, and seven of eight showed evidence of fluid retention. In some patients, the ratio of vascular volume to total tumor volume increased significantly (P < .001) within 24 hours following CDP860 administration, an effect suggestive of recruitment of previously non-functioning vessels.

CONCLUSION: These observations suggest that inhibition of PDGFR-ß might improve delivery of a concurrently administered therapy. However, in cancer patients, further exploration of the dosing regimen of CDP860 is required to dissociate adverse effects from beneficial effects. The findings challenge the view that inhibition of PDGF alone is beneficial, and confirm that effects of PDGFR kinase inhibition mediate, to some extent, the fluid retention observed in patients treated with mixed tyrosine kinase inhibitors.

Supported by Celltech R & D Ltd, Slough, UK.

Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. L. Lewis, L. D. Lewis, J. P. Eder, N. J. Reddy, F. Guo, K. J. Pierce, A. J. Olszanski, and R. B. Cohen Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers J. Clin. Oncol., November 1, 2009; 27(31): 5262 - 5269. [Abstract] [Full Text] [PDF]

				D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini, M. E. Hallin, G. R. Wickman, K. Amundson, J. H. Chen, D. A. Rewolinski, S. Yamazaki, E. Y. Wu, et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Clin. Cancer Res., November 15, 2008; 14(22): 7272 - 7283. [Abstract] [Full Text] [PDF]

				P S MURPHY, T J McCARTHY, and A S K DZIK-JURASZ The role of clinical imaging in oncological drug development Br. J. Radiol., September 1, 2008; 81(969): 685 - 692. [Abstract] [Full Text] [PDF]

				M. J. Overbeek, G. P. van Nieuw Amerongen, A. Boonstra, E. F. Smit, and A. Vonk-Noordegraaf Possible role of imatinib in clinical pulmonary veno-occlusive disease Eur. Respir. J., July 1, 2008; 32(1): 232 - 235. [Abstract] [Full Text] [PDF]

				C. Roberts, G. J. M. Parker, C. J. Rose, Y. Watson, J. P. O'Connor, S. M. Stivaros, A. Jackson, and V. E. Rushton Glandular Function in Sjogren Syndrome: Assessment with Dynamic Contrast-enhanced MR Imaging and Tracer Kinetic Modeling--Initial Experience Radiology, March 1, 2008; 246(3): 845 - 853. [Abstract] [Full Text] [PDF]

				J. Floege, F. Eitner, and C. E. Alpers A New Look at Platelet-Derived Growth Factor in Renal Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 12 - 23. [Abstract] [Full Text] [PDF]

				N.C. Ton, G.J.M. Parker, A. Jackson, S. Mullamitha, G.A. Buonaccorsi, C. Roberts, Y. Watson, K. Davies, S. Cheung, L. Hope, et al. Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2 Clin. Cancer Res., December 1, 2007; 13(23): 7113 - 7118. [Abstract] [Full Text] [PDF]

				J. P.B. O'Connor, G. C. Jayson, A. Jackson, D. Ghiorghiu, B. M. Carrington, C. J. Rose, S. J. Mills, R. Swindell, C. Roberts, C. L. Mitchell, et al. Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma Clin. Cancer Res., October 15, 2007; 13(20): 6130 - 6135. [Abstract] [Full Text] [PDF]

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				A. Quintas-Cardama, H. Kantarjian, S. O'Brien, G. Borthakur, J. Bruzzi, R. Munden, and J. Cortes Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure J. Clin. Oncol., September 1, 2007; 25(25): 3908 - 3914. [Abstract] [Full Text] [PDF]

				A. Jackson, J. P.B. O'Connor, G. J.M. Parker, and G. C. Jayson Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Clin. Cancer Res., June 15, 2007; 13(12): 3449 - 3459. [Abstract] [Full Text] [PDF]

				J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306. [Abstract] [Full Text] [PDF]

				A. P. Hall Review of the Pericyte during Angiogenesis and its Role in Cancer and Diabetic Retinopathy Toxicol Pathol, October 1, 2006; 34(6): 763 - 775. [Full Text] [PDF]

				A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, et al. Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer J. Clin. Oncol., January 10, 2006; 24(2): 217 - 227. [Abstract] [Full Text] [PDF]

				K. Pietras and D. Hanahan A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer J. Clin. Oncol., February 10, 2005; 23(5): 939 - 952. [Abstract] [Full Text] [PDF]